Artiva Biotherapeutics, Inc. Operating Income
Artiva Biotherapeutics, Inc. (ARTV) reported Operating Income of -$26.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Artiva Biotherapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$26.89M.
- Artiva Biotherapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$24.43M.
- Artiva Biotherapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$21.93M.
- Artiva Biotherapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$22.90M.
- Artiva Biotherapeutics, Inc. operating income (loss) for fiscal 2025 was -$89.81M.
- Artiva Biotherapeutics, Inc. operating income (loss) for fiscal 2024 was -$67.28M.
- Artiva Biotherapeutics, Inc. operating income (loss) for fiscal 2023 was -$30.67M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.89M 10-Q · filed 2026-08-06 | -$51.32M 10-Q · filed 2026-08-06 | -$73.25M derived: sum of 3 quarters · filed 2026-08-06 | -$96.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$24.43M 10-Q · filed 2026-05-08 | -$46.36M derived: sum of 2 quarters · filed 2026-05-08 | -$69.26M derived: sum of 3 quarters · filed 2026-05-08 | -$92.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$21.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$44.83M derived: sum of 2 quarters · filed 2026-03-10 | -$67.64M derived: sum of 3 quarters · filed 2026-08-06 | -$89.81M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$22.90M 10-Q · filed 2025-11-12 | -$45.71M derived: sum of 2 quarters · filed 2026-08-06 | -$67.88M 10-Q · filed 2025-11-12 | -$86.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$22.81M 10-Q · filed 2026-08-06 | -$44.98M 10-Q · filed 2026-08-06 | -$63.25M derived: sum of 3 quarters · filed 2026-08-06 | -$81.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$22.17M 10-Q · filed 2026-05-08 | -$40.44M derived: sum of 2 quarters · filed 2026-05-08 | -$58.77M derived: sum of 3 quarters · filed 2026-05-08 | -$74.96M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$36.60M derived: sum of 2 quarters · filed 2026-03-10 | -$52.79M derived: sum of 3 quarters · filed 2026-03-10 | -$67.28M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$18.34M 10-Q · filed 2025-11-12 | -$34.52M derived: sum of 2 quarters · filed 2025-11-12 | -$49.02M 10-Q · filed 2025-11-12 | -$60.99M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$16.19M 10-Q · filed 2025-08-06 | -$30.68M 10-Q · filed 2025-08-06 | -$42.65M derived: sum of 3 quarters · filed 2025-08-06 | -$31.84M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$14.49M 10-Q · filed 2025-05-08 | -$26.46M derived: sum of 2 quarters · filed 2025-05-08 | -$15.65M derived: sum of 3 quarters · filed 2025-05-08 | -$27.48M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$11.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$1.16M derived: sum of 2 quarters · filed 2025-03-24 | -$12.98M derived: sum of 3 quarters · filed 2025-03-24 | -$30.67M 10-K · filed 2025-03-24 |
| 2023-09-30 | $10.81M 10-Q · filed 2024-11-12 | -$1.01M derived: sum of 2 quarters · filed 2024-11-12 | -$18.70M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$11.82M 10-Q · filed 2024-08-29 | -$29.51M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |